Prostate cancer
Conditions
Interventions
Gold Standard:1. Criteria for Gleason score: Gleason score was performed according to the 2019 International Society of Urological Pathology (ISUP) guidelines on biopsy or radical prostatectomy specim
Index test:1. MRI Cytometry Assessment Model for Prostate Cancer
2. Molecular Imaging Assessment Model for Prostate Cancer
Sponsors
First Medical Center of Chinese PLA General Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Healthy Volunteers: 1. No prior history of prostate-related diseases or treatments; 2. Aged >= 18 years; 3. Signed informed consent prior to MRI examination. Patients with Suspected Prostate Tumor: 1. Underwent complete prostate conventional MRI, MR cytometry (TDD, IVIM, DKI, MD-MRI), and molecular metabolic imaging (APT, hyperpolarized MRI) due to clinical suspicion of prostate cancer; 2. Pathologically confirmed prostate cancer by biopsy within 3 months after MRI examination; 3. Underwent radical prostatectomy at our institution within 3 months after MRI examination.
Exclusion criteria
Exclusion criteria: Healthy Volunteers: 1. Unable to complete multiple MRI scans due to physical or psychological reasons; 2. MRI findings suggestive of prostate-related diseases (e.g., severe benign prostatic hyperplasia, prostatitis, etc.). Patients with Suspected Prostate Tumor: 1. Lesions not visible on MRI (PI-RADS < 3); 2. Prior history of prostate-related treatments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the receiver operating characteristic curve;Sensitivity;Specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Accuracy; | — |
Countries
China
Contacts
Public ContactWang Haiyi
First Medical Center of Chinese PLA General Hospital
Outcome results
None listed